专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

US20190263900A1 M-CSF SPECIFIC MONOCLONAL ANTIBODY AND USES THEREOF 审中-公开
公开(公告)号：US20190263900A1
公开(公告)日：2019-08-29
申请号：US16158642
申请日：2018-10-12
申请人： NOVARTIS VACCINES AND DIAGNOSTICS, INC. , XOMA TECHNOLOGY LTD.
发明人： Cheng Liu , Deborah Lee Zimmerman , Gregory Martin Harrowe , Kirston Koths , William Michael Kavanaugh , Li Long , Maria Calderon-Cacia , Arnold Horwitz
IPC分类号： C07K16/24 , A61K39/395 , A61K31/663 , A61K45/06 , A61K31/675
摘要： M-CSF-specific RX1-based or RX-1 derived antibodies are provided, along with pharmaceutical compositions containing such antibody, kits containing a pharmaceutical composition, and methods of preventing and treating bone loss in a subject afflicted with an osteolytic disease.

2. 发明申请

US20150368304A1 NUCLEIC ACIDS AND PROTEINS FROM STREPTOCOCCUS GROUPS A AND B 有权
标题翻译：来自STREPTOCOCCUS组A和B的核酸和蛋白质
公开(公告)号：US20150368304A1
公开(公告)日：2015-12-24
申请号：US14751790
申请日：2015-06-26
申请人： Novartis Vaccines and Diagnostics, Inc. , J. Craig Venter Institute
发明人： John TELFORD , Vega MASIGNANI , Maria SCARSELLI , Guido GRANDI , Herve TETTELIN , Claire FRASER
IPC分类号： C07K14/315 , C12N9/10 , C07K16/40 , C07K16/12
CPC分类号： C07K14/315 , A61K38/00 , A61K39/00 , A61K39/092 , A61K2039/505 , A61K2039/53 , C07K16/1275 , C07K16/40 , C07K2319/00 , C12N9/1088 , C12Y205/01018 , Y02A50/464 , Y02A50/466
摘要： The invention provides proteins from group B streptococcus (Streptococcus agalactiae) and group A streptococcus (Streptococcus pyogenes), including amino acid sequences and the corresponding nucleotide sequences. Data are given to show that the proteins are useful antigens for vaccines, immunogenic compositions, and/or diagnostics. The proteins are also targets for antibiotics.
摘要翻译：本发明提供来自B族链球菌（无乳链球菌）和A型链球菌（化脓链球菌）的蛋白质，包括氨基酸序列和相应的核苷酸序列。给出数据以显示蛋白质是疫苗，免疫原性组合物和/或诊断的有用抗原。蛋白质也是抗生素的靶标。

3. 发明申请

US20150072016A1 Microparticles with adsorbed polynucleotide-containing species 审中-公开
标题翻译：具有吸附的含多核苷酸物质的微粒
公开(公告)号：US20150072016A1
公开(公告)日：2015-03-12
申请号：US14543221
申请日：2014-11-17
申请人： Novartis Vaccines and Diagnostics, Inc.
发明人： Derek O'HAGAN , Manmohan SINGH
IPC分类号： A61K47/34 , A61K9/14 , C12N7/00 , A61K39/21
CPC分类号： A61K47/34 , A61K9/14 , A61K9/1647 , A61K9/167 , A61K31/7088 , A61K39/21 , A61K2039/55511 , C12N7/00 , C12N2740/16022 , C12N2740/16371
摘要： Microparticles with adsorbed polynucleotide-containing species, compositions containing the same, methods of making such microparticles, and uses thereof are disclosed. The microparticles comprise (a) a biodegradable polymer, such as a polyhydroxy butyric acid, a polycaprolactone, a polyorthoester, a polyanhydride, or a polycyanoacrylate, (b) a cationic surfactant such as cetyltrimethylammonium bromide, (c) and a polynucleotide-containing species adsorbed on the surface of the microparticles, wherein the polynucleotide-containing species constitutes at least 5 percent of the total weight of said microparticles. Examples of polynucleotide-containing species include polynucleotide-containing immunological adjuvants, such as CpG oligonucleotides, and polynucleotide-containing species that encode polypeptide-containing antigens, such as RNA and DNA vector constructs. Methods of delivering a therapeutic amount of a polynucleotide-containing species to a host animal, methods of stimulating an immune response, methods of treating a host animal having a pathogenic organism infection, methods of immunizing a host animal against infection by a pathogenic organism, and uses of the microparticle compositions for vaccines are also provided.
摘要翻译：公开了具有吸附的含多核苷酸的微粒，含有它们的组合物，制备这种微粒的方法及其用途。微粒包括（a）可生物降解的聚合物，例如多羟基丁酸，聚己内酯，聚原酸酯，聚酐或聚氰基丙烯酸酯，（b）阳离子表面活性剂如十六烷基三甲基溴化铵，（c）和含多核苷酸的物质吸附在微粒表面上，其中含多核苷酸的物质占所述微粒总重量的至少5％。含多核苷酸的物质的实例包括含多核苷酸的免疫佐剂，例如CpG寡核苷酸，以及编码含多肽的抗原的含多核苷酸的物种，例如RNA和DNA载体构建体。将治疗量的含多核苷酸的物质递送至宿主动物的方法，刺激免疫应答的方法，治疗具有致病性生物体感染的宿主动物的方法，免疫宿主动物免受病原体感染的方法，以及还提供了微粒组合物用于疫苗的用途。

4. 发明申请

US20140349932A1 ANGIOGENICALLY EFFECTIVE UNIT DOSE OF FGF-2 AND METHOD OF USE 审中-公开
标题翻译： FGF-2的有效单位剂量及其使用方法
公开(公告)号：US20140349932A1
公开(公告)日：2014-11-27
申请号：US14311523
申请日：2014-06-23
申请人： Novartis Vaccines and Diagnostics, Inc.
发明人： Martha Jo Whitehouse
IPC分类号： A61K38/18
CPC分类号： A61K38/1825 , A61K2300/00
摘要： The present invention provides a unit dose composition comprising 0.2 μg/kg to 48 μg/kg of an FGF-2 of SEQ ID NO:2, or an angiogenically active fragment or mutein thereof in a pharmaceutically acceptable carrier. Also provided is a method for treating a human patient for coronary artery disease, comprising administering into one or more coronary vessels or a peripheral vein of said patient a safe and angiogenically effective dose of a recombinant FGF-2, or an angiogenically active fragment or mutein thereof. Also provided is a pharmaceutical composition comprising a therapeutically effective amount of FGF-2, alone or in combination with heparin, in a therapeutically effective carrier.
摘要翻译：本发明提供在药学上可接受的载体中包含0.2μg/ kg至48μg/ kg的SEQ ID NO：2的FGF-2或其血管生成活性片段或突变蛋白的单位剂量组合物。还提供了一种用于治疗人类患者冠状动脉疾病的方法，包括向所述患者的一个或多个冠状动脉血管或外周静脉施用安全和血管生成有效剂量的重组FGF-2或血管生成活性片段或突变蛋白其中。还提供了药物组合物，其在治疗有效的载体中包含治疗有效量的单独或与肝素组合的FGF-2。

5. 发明申请

US20150024002A1 ALPHAVIRUS VECTORS FOR RESPIRATORY PATHOGEN VACCINES 有权
标题翻译：呼吸道病毒疫苗的ALVHAVIRUS矢量
公开(公告)号：US20150024002A1
公开(公告)日：2015-01-22
申请号：US14463831
申请日：2014-08-20
申请人： NOVARTIS VACCINES AND DIAGNOSTICS, INC.
发明人： Silvia Perri , John Polo , Yasushi Uematsu , Catherine Greer
IPC分类号： A61K39/12 , A61K39/145
CPC分类号： A61K39/12 , A61K39/145 , A61K39/155 , A61K2039/5252 , A61K2039/5256 , A61K2039/53 , A61K2039/543 , A61K2039/545 , A61K2039/55544 , A61K2039/55566 , A61K2039/70 , C12N15/86 , C12N2760/16122 , C12N2760/16134 , C12N2760/18322 , C12N2760/18334 , C12N2760/18522 , C12N2760/18534 , C12N2760/18622 , C12N2760/18634 , C12N2770/20022 , C12N2770/20034 , C12N2770/36143 , C12N2830/20 , C12N2830/60 , C12N2840/20 , C12N2840/203
摘要： Described herein are compositions and methods for stimulating an immune response to one or more proteins derived from one or more respiratory pathogens. In particular, the invention relates to alphavirus replicons, alphavirus vector constructs, alphavirus replicon particles expressing one or more antigens derived from one or more respiratory pathogens as well as to method of making and using these immunogenic compositions.
摘要翻译：本文描述了用于刺激来自一种或多种呼吸道病原体的一种或多种蛋白质的免疫应答的组合物和方法。特别地，本发明涉及甲病毒复制子，甲病毒载体构建体，表达一种或多种来自一种或多种呼吸道病原体的抗原的甲病毒复制子颗粒以及制备和使用这些免疫原性组合物的方法。

6. 发明申请

US20140161887A1 ADJUVANT COMPOSITIONS 审中-公开
标题翻译：补充剂组合物
公开(公告)号：US20140161887A1
公开(公告)日：2014-06-12
申请号：US14081986
申请日：2013-11-15
申请人： Novartis Vaccines and Diagnostics, Inc.
发明人： Derek O'Hagan , Nicholas Valiante
IPC分类号： A61K39/39
CPC分类号： A61K39/39 , A61K39/095 , A61K39/21 , A61K39/29 , A61K2039/55522 , A61K2039/55555 , A61K2039/55561 , A61K2039/55566 , C12N7/00 , C12N2740/16034 , C12N2770/24234
摘要： Adjuvant compositions comprising type 1 interferon inducers, such as double-stranded RNA, in combination with antigen delivery systems and/or immunostimulatory molecules, such as immunostimulatory nucleic acid sequences, for enhancing the immune response of a coadministered antigen, are described.
摘要翻译：描述了包含1型干扰素诱导剂（例如双链RNA）与抗原递送系统和/或免疫刺激分子（例如免疫刺激性核酸序列）组合的辅助组合物，用于增强共同施用的抗原的免疫应答。

7. 发明申请

US20140099719A1 METHOD FOR PRODUCING YEAST EXPRESSED HPV TYPES 6 AND 16 CAPSID PROTEINS 审中-公开
标题翻译：用于生产YEAST EXPRESSED HPV HPV 6型和16型CAPSID蛋白的方法
公开(公告)号：US20140099719A1
公开(公告)日：2014-04-10
申请号：US13893821
申请日：2013-05-14
申请人： Novartis Vaccines and Diagnostics, Inc.
发明人： Daniela Tornese Buonamassa , Catherine E. Greer , Cesira L. Galeotti , Giuliano Bensi , Roberto Petracca
IPC分类号： C12N15/81
CPC分类号： C12N15/81 , A61K2039/5258 , C07K2319/00 , C12N7/00 , C12N2710/20023 , C12N2800/102 , C12N2800/108
摘要： Mosaic VLPs of viral capsid proteins from different virus types are described, as are methods of making the same. Specifically, a diploid yeast strain that coexpresses the L1 and L2 capsid proteins of both HPV-6 and HPV-16 as mosaic VLPs is described. The mosaic VLPs induced the production of conformational antibodies against both L1 proteins upon administration to mice.
摘要翻译：描述了来自不同病毒类型的病毒衣壳蛋白的马赛克VLP，以及制备相同的方法。具体地说，描述了共表达HPV-6和HPV-16的L1和L2衣壳蛋白作为马赛克VLP的二倍体酵母菌株。在施用于小鼠后，马赛克VLP诱导针对两种L1蛋白的构象抗体的产生。

8. 发明授权

US09598469B2 HIV-1 south african subtype C env proteins 有权
公开(公告)号：US09598469B2
公开(公告)日：2017-03-21
申请号：US14141396
申请日：2013-12-26
申请人： Novartis Vaccines and Diagnostics, Inc. , University of Stellenbosch
发明人： Jan Zur Megede , Susan Barnett , Ying Lian , Susan Engelbrecht , Estrelita Janse Van Rensberg , Thomas J. Scriba
IPC分类号： A61K39/21 , C07K14/005 , C12N15/86 , A61K39/12 , A61K39/00
CPC分类号： C07K14/005 , A61K39/00 , A61K39/12 , A61K39/21 , A61K2039/53 , C12N15/86 , C12N2720/00034 , C12N2740/16043 , C12N2740/16052 , C12N2740/16122 , C12N2740/16222 , C12N2740/16322 , C12N2799/027 , C12N2800/108 , C12N2830/42 , C12N2840/203
摘要： The present invention relates to polynucleotides encoding immunogenic HIV polypeptides. Uses of the polypeptides in applications including immunization, generation of packaging cell lines, and production of HIV polypeptides are also described. Polynucleotides encoding antigenic HIV polypeptides are described, as are uses of these polynucleotides and polypeptide products therefrom, including formulations of immunogenic compositions and uses thereof.

9. 发明申请

US20140142038A1 ANGIOGENICALLY EFFECTIVE UNIT DOSE OF FGF AND METHOD OF ADMINISTERING 审中-公开
标题翻译： FGF的有效单位剂量和管理方法
公开(公告)号：US20140142038A1
公开(公告)日：2014-05-22
申请号：US14099143
申请日：2013-12-06
申请人： Novartis Vaccines and Diagnostics, Inc.
发明人： Martha J. Whitehouse , W. Michael Kavanaugh
IPC分类号： A61K38/18 , C07K14/50 , A61K31/727
CPC分类号： A61K38/1825 , A61K31/726 , C07K14/50
摘要： The present invention provides a unit dose comprising 0.2 μg/kg to 36 μg/kg of a recombinant FGF or an angiogenically active fragment or mutein thereof. Also provided is a pharmaceutical composition comprising an angiogenically effective dose of an FGF or an angiogenically active fragment or mutein thereof, and a pharmaceutically acceptable carrier. Also provided is a method for treating a human patient for coronary artery disease, comprising administering into at least one coronary vessel of said patient a safe and angiogenically effective dose of a recombinant FGF of any of SEQ ID NOS:1-3, 5, 8-10, or 12-14, or an angiogenically active fragment or mutein thereof.
摘要翻译：本发明提供了包含0.2μg/ kg至36μg/ kg的重组FGF或其血管生成活性片段或突变蛋白的单位剂量。还提供了包含血管生成有效剂量的FGF或其血管生成活性片段或突变蛋白和药学上可接受的载体的药物组合物。还提供了治疗人类患者冠状动脉疾病的方法，包括向所述患者的至少一个冠状血管施用安全和血管生成有效剂量的SEQ ID NO：1-3,5,8中任一项的重组FGF -10或12-14，或其血管生成活性片段或突变蛋白。

10. 发明申请

US20130095552A1 NOROVIRUS AND SAPOVIRUS ANTIGENS 有权
标题翻译： NOROVIRUS和SAPOVIRUS抗原
公开(公告)号：US20130095552A1
公开(公告)日：2013-04-18
申请号：US13686837
申请日：2012-11-27
申请人： Novartis Vaccines and Diagnostics, Inc.
发明人： Doris Coit , Michael Houghton , Colin McCoin , Angelica Medina-Selby , Michael Vajdy
IPC分类号： C12N9/14
CPC分类号： C12N9/14 , A61K39/00 , A61K39/12 , A61K2039/5258 , A61K2039/53 , A61K2039/545 , A61K2039/55544 , A61K2039/55555 , C07K14/005 , C07K2319/00 , C07K2319/40 , C12N2770/16022 , C12N2770/16034
摘要： Immunogenic compositions that elicit immune responses against Norovirus and Sapovirus antigens are described. In particular, the invention relates to polynucleotides encoding one or more capsid proteins or other immunogenic viral polypeptides from one or more strains of Norovirus and/or Sapovirus, coexpression of such immunogenic viral polypeptides with adjuvants, and methods of using the polynucleotides in applications including immunization and production of immunogenic viral polypeptides and viral-like particles (VLPs). Methods for producing Norovirus- or Sapovirus-derived multiple epitope fusion antigens or polyproteins and immunogenic compositions comprising one or more immunogenic polypeptides, polynucleotides, VLPs, and/or adjuvants are also described. The immunogenic compositions of the invention may also contain antigens other than Norovirus or Sapovirus antigens, including antigens that can be used in immunization against pathogens that cause diarrheal diseases, such as antigens derived from rotavirus.
摘要翻译：描述了引起针对诺如病毒和曙红病毒抗原的免疫应答的免疫原性组合物。特别地，本发明涉及编码来自一种或多种诺如病毒和/或札幌病毒株的一种或多种衣壳蛋白或其它免疫原性病毒多肽的多核苷酸，这种免疫原性病毒多肽与佐剂的共表达，以及在包括免疫的应用中使用多核苷酸的方法以及产生免疫原性病毒多肽和病毒样颗粒（VLP）。还描述了用于生产包含一种或多种免疫原性多肽，多核苷酸，VLP和/或佐剂的诺如病毒或札幌病毒衍生的多表位融合抗原或多蛋白的免疫原性组合物的方法。本发明的免疫原性组合物还可以含有除诺如病毒或札幌病毒抗原以外的抗原，包括可用于免疫引起腹泻疾病的病原体的抗原，例如来源于轮状病毒的抗原。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式